

# Journal of Integrated

# OMICS

a methodological journal

## Editors-in-Chief

Carlos Lodeiro-Espiño

Florentino Fdez-Riverola

Jens Coorsen

Jose-Luís Capelo-Martínez

# JIOMICS

## Journal of Integrated OMICS

---

### Focus and Scope

Journal of Integrated OMICS, JIOMICS, provides a forum for the publication of original research papers, preliminary communications, technical notes and critical reviews in all branches of pure and applied "-omics", such as genomics, proteomics, lipidomics, metabolomics or metallomics. The manuscripts must address methodological development. Contributions are evaluated based on established guidelines, including the fundamental nature of the study, scientific novelty, and substantial improvement or advantage over existing technology or method. Original research papers on fundamental studies, and novel sensor and instrumentation development, are especially encouraged. It is expected that improvements will also be demonstrated within the context of (or with regard to) a specific biological question; ability to promote the analysis of molecular mechanisms is of particular interest. Novel or improved applications in areas such as clinical, medicinal and biological chemistry, environmental analysis, pharmacology and materials science and engineering are welcome.

### Editors-in-Chief

**Carlos Lodeiro-Espiño**, University NOVA of Lisbon, Portugal

**Florentino Fdez-Riverola**, University of Vigo, Spain

**Jens R. Coorsen**, Brock University, Ontario, Canada

**Jose-Luís Capelo-Martínez**, University NOVA of Lisbon, Portugal

### Regional editors

#### ASIA

---

**Nelson Cruz**  
Saudi Arabia

**Jens R. Coorsen**  
Brock University, Ontario, Canada

#### Europe

---

**Gilberto Igrejas**  
University of Trás-os-Montes and Alto Douro, Life Sciences and Environmental School, Centre of Genetics and Biotechnology  
Department of Genetics and Biotechnology, 5001-801 Vila Real, Portugal

#### South America

---

**Marco Aurélio Zezzi Arruda**  
University of Campinas - Unicamp

**Carlos H. I. Ramos**  
Chemistry Institute – UNICAMP, Brazil

#### Randen Patterson

Center for Computational Proteomics, The Pennsylvania State University, US

### Associated editors

#### AFRICA

---

**Saffaj Taouqif**  
Centre Universitaire Régional d'Interface, Université Sidi Mohamed Ben Abdallah, route d'Imouzzar-Fès, Morocco

Centre of Biomedical Magnetic Resonance, SGPGIMS Campus, India

**Canhua Huang**  
The State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, PR China

**Ching-Yu Lin**  
Institute of Environmental Health, College of Public Health, National Taiwan University, Taipei, Taiwan

**Chantragan Srisomsap**  
Chulabhorn Research Institute, Bangkok, Thailand

#### ASIA

---

**Amita Pal**  
Division of Plant Biology, Bose Institute, Kolkata, India

**Ashish Gupta**

**Debmalya Barh**  
Institute of Integrative Omics and Applied Biotechnology (IIOAB), India

**Eiji Kinoshita**

Department of Functional Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University, Japan

**Fan Chen**

Institute of Genetics and Developmental Biology, Chinese Academy of Sciences (CAS), China

**Ganesh Chandra Sahoo**

BioMedical Informatics Center of Rajendra Memorial Research Institute of Medical Science (RMRIMS), Patna, India

**Guangchuang Yu**

Institute of Life & Health Engineering, Jinan University, Guangzhou, China

**Hai-Lei Zheng**

School of Life Sciences, Xiamen University, China

**Hsin-Yi Wu**

Institute of Chemistry, Academia Sinica, Taiwan

**Ibrokhim Abdurakhmonov**

Institute of Genetics and Plant experimental Biology Academy of Sciences of Uzbekistan, Uzbekistan

**Jianghao Sun**

Food Composition and Method Development Lab, U.S. Dept. of Agriculture, Agricultural Research Services, Beltsville, USA

**Juan Emilio Palomares-Rius**

Forestry and Forest Products Research Institute, Tsukuba, Japan

**Jung Min Kim**

Liver and Immunology Research Center, Daejeon Oriental Hospital of Daejeon University, Republic of Korea

**Kobra Pourabdollah**

Razi Chemistry Research Center (RCRC), Shahreza Branch, Islamic Azad University, Shahreza, Iran

**Krishnakumar Menon**

Amrita Center for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences, Kochi, Kerala, India

**Mohammed Rahman**

Center of Excellence for Advanced Materials Research (CEAMR), King Abdulaziz University, Jeddah, Saudi Arabia

**Ningwei Zhao**

Life Science & Clinical Medicine Dept. : Shimadzu (China) Co., Ltd

**Poh-Kuan Chong**

National University of Singapore, Singapore

**Sanjay Gupta**

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, India

**Sanjeeva Srivastava**

Indian Institute of Technology (IIT) Bombay, India

**Suresh Kumar**

Department of Applied Chemistry, S. V. National Institute of Technology, Gujarat, India

**Toshihide Nishimura**

Department of Surgery I, Tokyo Medical University, Tokyo, Japan

**Vishvanath Tiwari**

Department of Biochemistry, Central University of Rajasthan, India

**Xuanxian Peng**

School of Life Sciences, Sun Yat-sen University, Guangzhou, China

**Youxiong Que**

National Research & Development Center for Sugarcane, China Agriculture Research System(CARS), Fujian Agriculture & Forestry University, Republic of China

**Yu Wang**

Department of Pharmacology and Pharmacy, the University of Hong Kong, China

**Zhiqiang Gao**

Department of Chemistry, National University of Singapore

---

**AUSTRALIA AND NEW ZEALAND****Emad Kiriakous**

Queensland University of Technology (QUT), Brisbane, Australia

**Joëlle Coumans-Moens**

School of Science and Technology, School of Medicine, University of New England, Australia

**Maurizio Ronci**

Mawson Institute, University of South Australia, Mawson Lakes, Australia

**Michelle Colgrave**

CSIRO Livestock Industries, St Lucia, Australia

**Peter Hoffmann**

Institute for Photonics & Advanced Sensing (IPAS), School of Chemistry and Physics, University of Adelaide, Australia

**Valerie Wasinger**

Bioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, University of NSW, Australia

**Wujun Ma**

Centre for Comparative Genomics, Murdoch University, Australia

---

**EUROPE****AhmetKoc, PhD**

Izmir Institute of Technology, Department of Molecular Biology & Genetics, Urla, Izmir, Turkey

**Alejandro Gella**

Department of Basic Sciences, Neuroscience Laboratory, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès-08195, Barcelona, Spain

**Angelo D'Alessandro**

Università degli Studi della Tuscia, Department of Ecological and Biological Sciences, Viterbo, Italy

**Antonio Gnoni**

Department of Medical Basic Sciences, University of Bari "Aldo Moro", Bari, Italy

**Ana Varela Coelho**

Instituto de Tecnologia Química e Biológica (ITQB) Universidade Nova de Lisboa (UNL), Portugal

**Anna Maria Timperio**

Dipartimento Scienze Ambientali Università della Tuscia Viterbo, Italy

**Andrea Scaloni**

Proteomics and Mass Spectrometry Laboratory, ISPAAM, National Research Council, via Argine 1085, 80147 Napoli, Italy

**Angel P. Diz**

Department of Biochemistry, Genetics and Immunology, Faculty of Biology, University of Vigo, Spain

**Angela Chambery**

Department of Life Science, Second University of Naples, Italy

**Anna-Irini Koukkou**

University of Ioannina, Department of Chemistry, Biochemistry Laboratory, Greece

**António Sebastião Rodrigues**

Departamento de Genética, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Portugal

**Arzu Umar**

Department of Medical Oncology, Laboratory of Breast Cancer Genomics and Proteomics, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands

**Bart Devreese**

Laboratory for Protein Biochemistry and Biomolecular Engineering, Department for Biochemistry and Microbiology, Ghent University, Belgium

**Bernard Corfe**

Department of Oncology, University of Sheffield, Royal Hallamshire Hospital, United Kingdom

**Bruno Manadas**

Center for Neuroscience and Cell Biology, University of Coimbra, Portugal

**Carla Pinheiro**

Plant Sciences Division, Instituto de Tecnologia Química e Biológica (ITQB), Universidade Nova de Lisboa, Portugal

**Claudia Desiderio**

Consiglio Nazionale delle Ricerche, Istituto di Chimica del Riconoscimento Molecolare (UOS Roma), Italy

**Claudio De Pasquale**

SAGa Department, University of Palermo, Italy

**Celso Vladimiro Cunha**

Medical Microbiology Department, Institute of Hygiene and Tropical Medicine, New University of Lisbon, Portugal

**Christian Lindermayr**

Institute of Biochemical Plant Pathology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

**Christiane Fæste**

Section for Chemistry and Toxicology Norwegian Veterinary Institute, Oslo, Norway

**Christophe Cordella**

UMR1145 INRA, Laboratoire de Chimie Analytique, Paris, France

**Cosima Damiana Calvano**

Università degli Studi di Bari, Dipartimento di Chimica, Bari, Italy

**Daniela Cecconi**

Dip. di Biotecnologie, Laboratori di Proteomica e Spettrometri di Massa, Università di Verona, Verona, Italy

**Deborah Penque**

Departamento de Genética, Instituto Nacional de Saúde Dr Ricardo Jorge (INSA, I.P.), Lisboa, Portugal

**Dilek Battal**

Mersin University, Faculty of Pharmacy, Department of Toxicology, Turkey

**Domenico Garozzo**

CNR ICTP, Catania, Italy

**Ed Dudley**

Institute of Mass Spectrometry, College of Medicine Swansea University, Singleton Park, Swansea, Wales, UK

**Elia Ranzato**

Dipartimento di Scienze e Innovazione Tecnologica, DiSIT, University of Piemonte Orientale, Alessandria, Italy

**Elisa Bona**

Università del Piemonte Orientale, DISIT, Alessandria, Italy

**Elke Hammer**

Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt Universität, Germany

**Enrica Pessione**

University of Torino, Life Sciences and Systems Biology Department, Torino, Italy

**Federica Pellati**

Department of Life Sciences, University of Modena and Reggio Emilia, Italy

**François Fenaille**

CEA, IBIteCS, Service de Pharmacologie et D'Immunoanalyse (SPI), France

**Fulvio Magni**

Department of Health Science, Monza, Italy

**Georgios Theodoridis**

Department of Chemistry, Aristotle University, Greece

**Gianfranco Romanazzi**

Department of Environmental and Crop Sciences, Marche Polytechnic University, Italy

**Giorgio Valentini**

Università degli Studi di Milano, Dept. of Computer Science, Italy

**Helen Gika**

Chemical Engineering Department, Aristotle University of Thessaloniki, Greece

**Hugo Miguel Baptista Carreira dos Santos**

REQUIMTE-FCT Universidade NOVA de Lisboa, Portugal

**Iñaki Álvarez**

Institut de Biotecnologia i Biomedicina Vicent Villar Palasí, Universitat Autònoma de Barcelona, Barcelona

**Jane Thomas-Oates**

Centre of Excellence in Mass Spectrometry and Department of Chemistry, University of York, Heslington, UK

**Jens Allmer**

Molecular Biology and Genetics, Izmir Institute of Technology, Urla, Izmir, Turkey

**Jesús Jorrín Novo**

Agricultural and Plant Biochemistry, Proteomics Research Group, Department of Biochemistry and Molecular Biology, Córdoba, Spain

**Johan Palmfeldt**

Research Unit for Molecular Medicine, Aarhus University Hospital, Skejby, Aarhus, Denmark

**Jose Câmara**

University of Madeira, Funchal, Portugal

**Juraj Gregan**

Max F. Perutz Laboratories, University of Vienna, Austria

**Karin Stensjö**

Department of Photochemistry and Molecular Science, Ångström Laboratory, Uppsala University, Sweden

**Kay Ohlendieck**

Department of Biology, National University of Ireland, Maynooth, Co. Kildare, Ireland

**Konstantinos Kouremenos**

Department of Chemistry, Umea University, Sweden

**Luisa Brito**

Laboratório de Microbiologia, Instituto Superior de Agronomia, Tapada da Ajuda, Lisbon, Portugal

**Marco Lemos**

GIRM & ESTM - Polytechnic Institute of Leiria, Peniche, Portugal

**María Álava**

Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, Spain

**María de la Fuente**

Legume group, Genetic Resources, Mision Biologica de Galicia-CSIC, Pontevedra, Spain

**Maria Gabriela Rivas**

REQUIMTE/CQFB, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Portugal

**Marie Arul**

Muséum National Histoire Naturelle, Département RDDM, Plateforme de spectrométrie de masse et de protéomique, Paris, France

**Marie-Pierre Bousquet**

Institut de Pharmacologie et de Biologie Structurale, UPS/CNRS, Toulouse, France

**Mario Diniz**

Dept. Química-REQUIMTE, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Portugal

**Martina Marchetti-Deschmann**

Institute of Chemical Technologies and Analytics, Vienna University of Technology, Vienna, Austria

**Maxence Wisztorski**

University Lille 1, Laboratoire de Spectrométrie de Masse Biologique, Fondamentale & Appliquée, Villeneuve d'Ascq, France

**Michel Jaquinod**

Exploring the Dynamics of Proteomes/Laboratoire Biologie à Grande Echelle, Institut de Recherches en Technologies et Sciences pour le Vivant, Grenoble, France

**Mónica Botelho**

Centre for the study of animal sciences (CECA)/ICETA, Porto, Portugal

**Pantelis Bagos**

Department of Computer Science and Biomedical Informatics, University of Central Greece, Greece

**Patrice Francois**

Genomic Research Laboratory, Service of Infectious Diseases, Department of Internal Medicine, Geneva

**Patrícia Alexandra Curado Quintas Dinis Poeta**

University of Trás-os-Montes and Alto Douro (UTAD), School of Agrary and Veterinary Sciences, Veterinary, Science Department, Portugal

**Pedro Rodrigues**

Centro de Ciências do Mar do Algarve, CCMAR, Faro, Portugal

**Per Bruheim**

Department of Biotechnology, Norwegian University of Science and Technology, Trondheim, Norway

**Philipp Hess**

Institut Universitaire Mer et Littoral (CNRS - Université de Nantes - Ifremer), Nantes, France

**Pieter de Lange**

Dipartimento di Scienze della Vita, Seconda Università degli Studi di Napoli, Caserta, Italy

**Ralph Fingerhut**

University Children's Hospital, Swiss Newborn Screening Laboratory, Children's Research Center, Zürich, Switzerland

**Rubén Armañanzas**

Computational Intelligence Group, Departamento de Inteligencia Artificial, Universidad Politécnica de Madrid, Spain

**Ruth Birner-Gruenberger**

Medical University Graz, Austria

**Sebastian Galuska**

Institute of Biochemistry, Faculty of Medicine, Justus-Liebig-University of Giessen, Germany

**Serge Cosnier**

Department of Molecular Chemistry, Grenoble university/CNRS, Grenoble, France

**Serhat Döker**

Cankiri Karatekin University, Chemistry Department, Cankiri, Turkey

**Simona Martinotti**

Dipartimento di Scienze e Innovazione Tecnologica, DiSIT, University of Piemonte Orientale, Alessandria, Italy

**Spiros D. Garbis**

Biomedical Research Foundation of the Academy of Athens, Center for Basic Research - Division of Biotechnology, Greece

**Steeve Thany**

Laboratoire Récepteurs et Canaux Ioniques Membranaires, UFR Science, Université d'Angers, France

**Stefania Orrù**

University of Naples Parthenope, Naples, Italy

**Tâmara García Barrera**

Departamento de Química y Ciencia de los Materiales, Facultad de Ciencias Experimentales, Universidad de Huelva, Spain

**Vera Muccilli**

Dipartimento di Scienze Chimiche, Università di Catania, Catania, Italy

**Yuri van der Burgt**

Leiden University Medical Center, Department of Parasitology, The Netherlands

---

**SOUTH AMERICA**

---

**Andréa P.B. Gollucke**

Hexalab/Catholic University of Santos, Brazil

**Arlindo Moura**

Department of Animal Science - College of Agricultural Sciences - Federal University of Ceara, Fortaleza, Brazil

**Bruno Lomonte**

Instituto Clodomiro Picado, Universidad de Costa Rica

**Edson Guimarães Lo Turco**

São Paulo Federal University, Brazil

**Fabio Ribeiro Cerqueira**

Department of Informatics and NuBio (Research Group for Bioinformatics), University of Vicoso, Brazil

**Fernando Barbosa**

Faculty of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo, Brazil

**Mário Hiroyuki Hirata**

Laboratório de Biologia Molecular Aplicado ao Diagnóstico, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, Brazil

**Jan Schripsema**

Grupo Metabólica, Laboratório de Ciências Químicas, Universidade Estadual do Norte Fluminense, Campos dos Goytacazes, Brazil

**Jorg Kobarg**

Centro Nacional de Pesquisa em Energia e Materiais, Laboratório Nacional de Biociências, Brazil

**Rossana Arroyo**

Department of Infectomic and Molecular Biology, Center of Research and Advanced Studies of the National, Polytechnical Institute (CINVESTAV-IPN), Mexico City, Mexico

**Rubem Menna Barreto**

Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

**Vasco Azevedo**

Biological Sciences Institute, Federal University of Minas Gerais, Brazil

---

**NORTH AMERICA**

---

**Amosy M'Koma**

Vanderbilt University School of Medicine, Department of General Surgery, Colon and Rectal Surgery, Nashville, USA

**Anthony Gramolini**

Department of Physiology, Faculty of Medicine, University of Toronto, Canada

**Anas Abdel Rahman**

Department of Chemistry, Memorial University of Newfoundland and Labrador St. John's, Canada

**Christina Ferreira**

Purdue University - Aston Laboratories of Mass Spectrometry, Hall for Discovery and Learning Research, West Lafayette, US

**Eustache Paramithiotis**

Caprion Proteomics Inc., Montreal, Canada

**Jagjit Yadav**

Microbial Pathogenesis and Toxicogenomics, Laboratory, Environmental Genetics and Molecular, Toxicology Division, Department of Environmental

Health, University of Cincinnati College of Medicine, Ohio, USA

**Jiaxu Li**

Department of Biochemistry and Molecular Biology, Mississippi State University, USA

**Laszlo Prokai**

Department of Molecular Biology & Immunology, University of North Texas Health Science Center, Fort Worth, USA

**Madhulika Gupta**

Children's Health Research Institute, University of Western Ontario London, ON, Canada

**Michael H.A. Roehrl**

Department of Pathology and Laboratory Medicine, Boston Medical Center Boston, USA

**Olga Trenchevska**

Molecular Biomarkers, Biodesign Institute at Arizona State University, USA

**Robert Powers**

University of Nebraska-Lincoln, Department of Chemistry, USA

**Susan Hester**

United States Environmental Protection Agency, Durnam, USA

**Thomas Kislinger**

Department of Medical Biophysics, University of Toronto, Canada

**William A LaFramboise**

Department of Pathology, University of Pittsburgh School of Medicine Shadyside Hospital, Pittsburgh, USA

**Xuequn Chen**

Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, USA

**Ying Qu**

Microdialysis Experts Consultant Service, San Diego, USA



# JOURNAL OF INTEGRATED OMICS

*A methodological  
Journal*

---

## EDITORIAL

---

Advancing Diversity, Equity, and Inclusion in Scientific Research, Public Health, and Biomedical Innovation 1


## ORIGINAL ARTICLES

---

Differential Urinary Proteomics and Absolute Protein Quantification Reveal Biomarkers of Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer 5

## EDITORIAL





# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



EDITORIAL | DOI: 10.5584/jiomics.v15i1.240

## Advancing Diversity, Equity, and Inclusion in Scientific Research, Public Health, and Biomedical Innovation

José L. Capelo<sup>1,2,\*</sup>, Carlos Lodeiro<sup>1,2</sup>, Sofia Pessanha<sup>3</sup>, Abel J. S. C. Vieira<sup>4</sup>, Maria Rosa Paiva<sup>5</sup>, Renata Freitas<sup>6,7,8</sup>, Isabel Fonseca<sup>9</sup>, Manuel D. Ortigueira<sup>10</sup>, Mauro Guerra<sup>3</sup>, Luis Lapão<sup>11,12</sup>

<sup>1</sup>(Bio)Chemistry & Omics, BIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, 2829-516 Caparica, Portugal. <sup>2</sup>PROTEOMASS Scientific Society, Praceta Jerónimo Dias, 2825-466 Costa da Caparica, Portugal. <sup>3</sup>LIBPhys, LA-REAL, NOVA School of Science and Technology, NOVA University of Lisbon, 2829-516 Caparica, Portugal. <sup>4</sup>Department of Chemistry, LAQV-REQUIMTE, Faculty of Sciences and Technology, NOVA University of Lisbon, Caparica, Portugal. <sup>5</sup>CENSE – Center for Environmental and Sustainability Research, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica, Portugal. <sup>6</sup>i3S – Institute of Research and Innovation in Health, Rua Alfredo Allen 208, Porto, 4200-135 Portugal. <sup>7</sup>Associate Laboratory i4HB – Institute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica, 2819-516 Portugal. <sup>8</sup>UCIBIO – Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica, 2819-516 Portugal. <sup>9</sup>LAQV/REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, 2829-516 Caparica, Portugal. <sup>10</sup>CTS–UNINOVA and DEE of NOVA School of Science and Technology, NOVA University of Lisbon, 2829-516, Caparica, Portugal. <sup>11</sup>UNIDEMI, Department of Mechanical and Industrial Engineering, NOVA School of Science and Technology, NOVA University of Lisbon, 2829-516, Caparica, Portugal. <sup>12</sup>WHO Collaborating Center on Health Workforce Policy and Planning, Instituto de Higiene e Medicina Tropical, NOVA University of Lisbon, Lisbon, Portugal.

**Available Online:** 15 April 2025

The intersection of Diversity, Equity, and Inclusion (DEI) has become a fundamental framework for addressing structural inequalities in scientific research, biomedical innovation, and public health. Empirical evidence indicates that heterogeneous research environments foster greater innovation, problem-solving capacity, and scientific productivity [1,2]. However, systemic barriers, including institutional discrimination, implicit bias, and intersectional inequalities, continue to limit the full participation of underrepresented groups in Science, Technology, Engineering and Mathematics (STEM) [3,4]. Addressing these disparities necessitates an interdisciplinary approach that integrates sociocultural determinants, policy interventions, and scientific methodologies to create a more equitable and inclusive research ecosystem.

### Underrepresentation, Intersectionality & Systemic Barriers in STEM

Despite global efforts to increase diversity in STEM disciplines, statistical analyses reveal that Black, Indigenous and People of Colour (BIPOC), women, Lesbian, Gay, Bisexual, Transgender and Queer or questioning (LGBTQ) individuals,

and people with disabilities remain underrepresented in research institutions, funding agencies, and editorial boards [2,5,6]. Implicit biases in recruitment, funding allocation, and authorship recognition contribute to cumulative disadvantages that disproportionately affect minority scholars [7].

Moreover, intersectionality, a framework that examines how overlapping social categorizations such as race, gender, socioeconomic status, and sexual orientation exacerbate inequality, provides a critical analytical tool for identifying hidden biases within scientific institutions [8,9].

Gender-based barriers continue to shape career progression, particularly for women in STEM. The "leaky pipeline" phenomenon, in which women and marginalized groups leave scientific careers due to unconscious bias, institutional exclusion, and limited access to mentorship, remains a pressing concern [10,11]. Addressing these disparities requires structural interventions, such as gender-affirming policies, equitable funding distribution, and fostering inclusivity in leadership roles [12,13].

\*Corresponding author: José L. Capelo, jlcapelom@bioscopegroup.org, Tel: +351 919 404 933

## Structural Inequities in Biomedical Research and Health Disparities

Sociocultural determinants of health, including race, ethnicity, gender identity, and socioeconomic status, significantly impact public health outcomes [14]. Persistent health inequities in access to mental health services, gender-affirming care, and reproductive healthcare disproportionately affect marginalized populations, including LGBTQ individuals, racial minorities, and Indigenous communities [15-18].

Biomedical research has historically excluded diverse populations, leading to racial disparities in clinical trials and underrepresentation in genomic databases, which subsequently affect diagnostic accuracy, treatment efficacy, and precision medicine [19]. Studies indicate that the failure to integrate diverse genetic backgrounds in Genome-Wide Association Studies (GWAS) has limited the applicability of precision medicine interventions for non-European populations [20,21]. To mitigate these disparities, researchers must promote community engagement, inclusive study designs, and culturally responsive methodologies [22].

Moreover, mental health disparities persist among historically marginalized communities, where factors such as oppression, stigma, and socioeconomic inequalities exacerbate psychological distress and limit healthcare access [23,24]. Advancing equitable mental health frameworks necessitates intersectional policy solutions that address both structural and sociocultural dimensions of healthcare [25].

## Environmental Justice, Climate Change and Public Health

The climate crisis disproportionately impacts vulnerable populations, particularly Indigenous communities, low-income groups, and racial minorities, who face greater exposure to environmental hazards [26]. Research indicates that pollution, climate change-induced displacement, and resource scarcity are exacerbating public health disparities. The integration of community diversity perspectives in environmental policymaking is essential for addressing climate-related inequities and promoting sustainable public health strategies. [27]

## Policy Recommendations and Institutional Accountability

To dismantle systemic barriers in scientific research, healthcare, and environmental policy, institutions must implement:

- Inclusive hiring and funding allocation frameworks that actively reduce biases in faculty recruitment, grant reviews, and tenure evaluations [28].

- Equitable authorship policies that recognize diverse contributions in interdisciplinary research teams [29].
- Mandatory DEI training across research institutions to combat unconscious bias and foster inclusive leadership [30].
- Diverse clinical trial recruitment strategies to ensure racial, ethnic, and gender inclusivity in biomedical research [31].
- Environmental justice policies that integrate sociocultural knowledge with scientific risk assessments to reduce climate vulnerability [32].

By adopting evidence-based strategies that prioritize diverse perspectives, equitable representation, and structural accountability, the scientific community can cultivate a more inclusive, resilient, and socially responsible research ecosystem.

## References

- [1] S. E. Page, *The Difference: How the Power of Diversity Creates Better Groups, Firms, Schools, and Societies* (New Edition). Princeton, USA: Princeton University Press, 2008. doi: 10.2307/j.ctt7sp9c.
- [2] B. Hofstra, V. V. Kulkarni, S. Munoz-Najar Galvez, B. He, D. Jurafsky, and D. A. McFarland, "The Diversity-Innovation Paradox in Science," *Proceedings of the National Academy of Sciences*, vol. 117, no. 17, pp. 9284–9291, Apr. 2020, doi: 10.1073/pnas.1915378117.
- [3] R. B. Freeman and W. Huang, "Collaborating with People Like Me: Ethnic Coauthorship within the United States," *J Labor Econ*, vol. 33, no. S1, pp. S289–S318, Jul. 2015, doi: 10.1086/678973.
- [4] E. O. McGee, "Interrogating Structural Racism in STEM Higher Education," *Educational Researcher*, vol. 49, no. 9, pp. 633–644, Dec. 2020, doi: 10.3102/0013189X20972718.
- [5] A. K. Sivan and A. L. Miller, "Breaking down invisible barriers for LGBTQIA+ in STEM," *Frontiers Communications, Science News*. Accessed: Mar. 24, 2025. [Online]. Available: <https://www.frontiersin.org/news/2023/06/22/invisible-barriers-lgbtqia-stem-aswathi-sivan-andrew-miller/>
- [6] L. M. Diele-Viegas et al., "Community voices: sowing, germinating, flourishing as strategies to support inclusion in STEM," *Nat Commun*, vol. 13, no. 1, p. 3219, Jun. 2022, doi: 10.1038/s41467-022-30981-6.
- [7] A. A. Eaton, J. F. Saunders, R. K. Jacobson, and K. West, "How Gender and Race Stereotypes Impact the Advancement

- of Scholars in STEM: Professors' Biased Evaluations of Physics and Biology Post-Doctoral Candidates," *Sex Roles*, vol. 82, no. 3–4, pp. 127–141, Feb. 2020, doi: 10.1007/s11199-019-01052-w.
- [8] K. Crenshaw, "Demarginalizing the Intersection of Race and Sex: A Black Feminist Critique of Antidiscrimination Doctrine, Feminist Theory and Antiracist Politics," *University of Chicago Legal Forum*, vol. 1989, no. 1, pp. 139–167, 1989, Accessed: Mar. 24, 2025. [Online]. Available: <https://chicagounbound.uchicago.edu/uclf/vol1989/iss1/8>
- [9] P. H. Collins, "Intersectionality's Definitional Dilemmas," *Annu Rev Sociol*, vol. 41, no. 1, pp. 1–20, Aug. 2015, doi: 10.1146/annurev-soc-073014-112142.
- [10] J. D. Speer, "Bye bye Ms. American Sci: Women and the leaky STEM pipeline," *Econ Educ Rev*, vol. 93, p. 102371, Apr. 2023, doi: 10.1016/j.econedurev.2023.102371.
- [11] M. Evagorou, B. Puig, D. Bayram, and H. Janeckova, "Addressing the gender gap in STEM education across educational levels – Analytical report," Brussels, Jul. 2024. doi: <https://data.europa.eu/doi/10.2766/260477>.
- [12] W. M. Williams and S. J. Ceci, "National hiring experiments reveal 2:1 faculty preference for women on STEM tenure track," *Proceedings of the National Academy of Sciences*, vol. 112, no. 17, pp. 5360–5365, Apr. 2015, doi: 10.1073/pnas.1418878112.
- [13] M. Reggiani, J. D. Gagnon, and R. J. Lunn, "A holistic understanding of inclusion in STEM: Systemic challenges and support for women and LGBT+ academics and PhD students," *Sci Educ*, vol. 108, no. 6, pp. 1637–1669, Nov. 2024, doi: 10.1002/sce.21899.
- [14] P. Braveman, S. Egerter, and D. R. Williams, "The Social Determinants of Health: Coming of Age," *Annu Rev Public Health*, vol. 32, no. 1, pp. 381–398, Apr. 2011, doi: 10.1146/annurev-publhealth-031210-101218.
- [15] I. H. Meyer, "Resilience in the study of minority stress and health of sexual and gender minorities," *Psychol Sex Orientat Gend Divers*, vol. 2, no. 3, pp. 209–213, Sep. 2015, doi: 10.1037/sgd0000132.
- [16] G. R. Bauer, R. Hammond, R. Travers, M. Kaay, K. M. Hohenadel, and M. Boyce, "I Don't Think This Is Theoretical; This Is Our Lives': How Erasure Impacts Health Care for Transgender People," *Journal of the Association of Nurses in AIDS Care*, vol. 20, no. 5, pp. 348–361, Sep. 2009, doi: 10.1016/j.jana.2009.07.004.
- [17] G. C. Gee and C. L. Ford, "STRUCTURAL RACISM AND HEALTH INEQUITIES," *Du Bois Rev*, vol. 8, no. 1, pp. 115–132, Apr. 2011, doi: 10.1017/S1742058X11000130.
- [18] L. J. Kirmayer and G. Brass, "Addressing global health disparities among Indigenous peoples," *The Lancet*, vol. 388, no. 10040, pp. 105–106, Jul. 2016, doi: 10.1016/S0140-6736(16)30194-5.
- [19] A. B. Popejoy and S. M. Fullerton, "Genomics is failing on diversity," *Nature*, vol. 538, no. 7624, pp. 161–164, Oct. 2016, doi: 10.1038/538161a.
- [20] J. N. Cooke Bailey, W. S. Bush, and D. C. Crawford, "Editorial: The Importance of Diversity in Precision Medicine Research," *Front Genet*, vol. 11, Aug. 2020, doi: 10.3389/fgene.2020.00875.
- [21] D. Ju, D. Hui, D. A. Hammond, A. Wonkam, and S. A. Tishkoff, "Importance of Including Non-European Populations in Large Human Genetic Studies to Enhance Precision Medicine," *Annu Rev Biomed Data Sci*, vol. 5, no. 1, pp. 321–339, Aug. 2022, doi: 10.1146/annurev-biodatasci-122220-112550.
- [22] A. A. Lemke et al., "Addressing underrepresentation in genomics research through community engagement," *The American Journal of Human Genetics*, vol. 109, no. 9, pp. 1563–1571, Sep. 2022, doi: 10.1016/j.ajhg.2022.08.005.
- [23] M. Fischer, J. Swint, W. Zhang, and X. Zhang, "Mind the Gap: Unraveling Mental Health Disparities in America's Diverse Landscape," Jul. 29, 2024. doi: 10.1101/2024.07.28.24311109.
- [24] M. Lednova, H. Brooks, J. Herve, J. Gangneux, and K. Kuhrova, "Mental Health in Cities: Beyond traditional healthcare services," Brussels, Dec. 2024.
- [25] C. L. Barksdale, E. Pérez-Stable, and J. Gordon, "Innovative Directions to Advance Mental Health Disparities Research," *American Journal of Psychiatry*, vol. 179, no. 6, pp. 397–401, Jun. 2022, doi: 10.1176/appi.ajp.21100972.
- [26] F. Belaïd and C. Unger, "Crafting effective climate, energy, and environmental policy: time for action," *Humanit Soc Sci Commun*, vol. 11, no. 1, p. 1357, Oct. 2024, doi: 10.1057/s41599-024-03762-3.
- [27] E. Bell and L. J. Schueman, "Why climate change is a public health issue." Accessed: Mar. 24, 2025. [Online]. Available: <http://oneearth.org/why-climate-change-is-a-public-health-issue/>
- [28] S. Meirmans et al., "Science policies: How should science funding be allocated? An evolutionary biologists' perspective," *J Evol Biol*, vol. 32, no. 8, pp. 754–768, Aug. 2019, doi: 10.1111/jeb.13497.


[29] Z. Lin, "Modernizing Authorship Criteria and Transparency Practices to Facilitate Open and Equitable Team Science," SSRN Electronic Journal, Jan. 2024, doi: 10.2139/ssrn.4958912.

[30] K. S. Holt, "How Can DEI Training Change the Culture of an Organization to Achieve Belonging and Retain Diverse Employees?," Portland State University, 2024. doi: 10.15760/honors.1598.

[31] J. Igwe et al., "Opportunities to Increase Science of Diversity and Inclusion in Clinical Trials: Equity and a Lack of a Control," J Am Heart Assoc, vol. 12, no. 24, Dec. 2023, doi: 10.1161/JAHA.123.030042.

[32] Y. O. Van Horne et al., "An applied environmental justice framework for exposure science,," J Expo Sci Environ Epidemiol, vol. 33, no. 1, pp. 1–11, Jan. 2023, doi: 10.1038/s41370-022-00422-z.

## ORIGINAL ARTICLES



ORIGINAL ARTICLE | DOI: 10.5584/jiomics.v15i1.245

## Differential Urinary Proteomics and Absolute Protein Quantification Reveal Biomarkers of Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer

João M.R.A Montes<sup>1,2</sup>, Luís B. Carvalho<sup>1,2</sup>, Inês F. Domingos<sup>1,2</sup>, André Q. Figueiredo<sup>1,2</sup>, Carlos Lodeiro<sup>1,2</sup>, Mariana Medeiros<sup>3,4</sup>, Luís Campos Pinheiro<sup>3,4</sup>, José Luis Capelo<sup>1,2</sup>, Hugo Miguel Santos<sup>1,2,\*</sup>

<sup>1</sup>BIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, Lisbon, 2829-516 Caparica, Portugal; <sup>2</sup>PROTEOMASS Scientific Society, Caparica, Portugal; <sup>3</sup>Urology Department, Central Lisbon Hospital Center, Lisbon, Portugal; <sup>4</sup>NOVA Medical School, NOVA University of Lisbon, Lisbon, Portugal.

**Available Online:** 15 April 2025

### ABSTRACT

A comparative urinary proteomic analysis using the Total Protein Approach (TPA) revealed distinct protein abundance profiles between patients with muscle-invasive (MIBC) and non-muscle-invasive bladder cancer (NMIBC), suggesting potential diagnostic utility. Notably, several proteins, including periostin (POSTN), immunoglobulin variable regions (IGLV3-21, IGHV3-49, IGHV5-51), and complement regulator (C4BPB), were found at significantly higher concentrations in the urine of MIBC patients. These findings support their value as non-invasive indicators of tumour aggressiveness. The TPA-based urinary protein signature holds promise for improving early risk stratification, detecting biological features associated with invasive disease, and may inform treatment strategies.

**Keywords:** Bladder cancer, Total protein approach, TPA, proteomics, classification, diagnostic.

### Introduction

Bladder cancer is the tenth most common malignancy worldwide, with an estimated 573,000 new cases and 213,000 deaths reported in 2020 alone [1]. Histologically, over 90% of bladder cancers in developed countries are urothelial carcinomas arising from the transitional epithelium lining the urinary tract [2,3]. A crucial determinant of prognosis and therapeutic decision-making is the depth of tumour invasion at diagnosis, which classifies tumours into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) [4]. While NMIBC generally carries a favourable prognosis and is often managed with bladder-sparing strategies, MIBC is associated with a significantly higher risk of progression, metastasis, and disease-specific mortality [5,6].

The distinction between NMIBC and MIBC is fundamentally

histopathological, based on the degree of tumour infiltration into the bladder wall [7]. NMIBC includes stages Ta (non-invasive papillary carcinoma), T1 (invasion into the lamina propria), and carcinoma in situ (CIS), a flat but high-grade lesion [8]. MIBC is defined by invasion into the muscularis propria (T2) or beyond (T3–T4) [9]. Accurate staging requires high-quality transurethral resection of bladder tumour (TURBT) specimens, including detrusor muscle to evaluate the depth of invasion [10,11].

In addition to morphological features, recent advances in molecular profiling have highlighted significant biological differences between NMIBC and MIBC. NMIBC is often determined by mutations in FGFR3, KDM6A, STAG2, and PIK3CA, which are typically linked with luminal differentiation and low-grade pathology [12]. MIBC, on the other hand, often carries mutations in TP53, RB1, ERBB2, and genes involved in DNA damage response, contributing to greater genomic instability and aggressive behaviour. Transcriptomic

\*Corresponding author: Hugo Miguel Santos, hmsantos@fct.unl.pt

studies have further stratified MIBC into molecular subtypes: luminal, basal, and neuroendocrine-like, each with distinct therapeutic vulnerabilities and clinical outcomes [13].

While histological classification remains essential, emerging evidence supports using urine-based biomarkers to enhance diagnostic precision, monitor disease progression, and guide treatment strategies [14]. Urine in direct contact with the urothelial lining is a valuable and non-invasive source of tumour-derived proteins [15]. Advances in mass spectrometry-based proteomics have enabled the identification of urinary protein signatures associated with tumorigenesis and invasiveness. Among various strategies, the Total Protein Approach, TPA, offers a label-free, quantitative method for estimating the absolute abundance of proteins within complex biological samples [16,17]. TPA relies on normalizing mass spectrometry signal intensities of individual proteins to the total protein signal and their respective molecular weights, enabling accurate and scalable quantification without needing internal standards [18].

In this study, we applied TPA to compare the urinary proteome of patients with NMIBC and MIBC. Our objective was to identify differentially expressed proteins reflecting key biological processes with the goal of establishing a urinary biomarker panel capable of distinguishing tumour invasiveness and supporting non-invasive clinical decision-making.

## Materials and Methods

### Patients' selection

Human mid-stream second void morning urine specimens were collected from patients with NMIBC and MIBC diagnoses confirmed by pathology examination, according to the study approval from the ethics board of the Central Lisbon Hospital Center – Hospital de São José (669/2018). The patients involved in the study were selected based on the following criteria: (a) Inclusion: clear bladder cancer diagnosis, and (b) Exclusion: patients with records of urinary cancer history, HIV or other viral infections such as Hepatitis B, C, organ transplant, and recent chemo/radiotherapy. The study population consisted of 24 patients: 12 with NMIBC (Ta bladder cancer stage) and 12 with MIBC (T2 or higher bladder cancer stages).

### Urine Sample Collection and Preparation

Urine samples were collected in 50 mL centrifuged tubes containing 38 mg of boric acid, preventing bacterial growth [19]. Samples containing visible haematuria were not included in our study, with the remaining being centrifuged at 5000 x *g* for 20 min to remove cell debris, followed by 10 mL aliquots of the resulting supernatants stored at -60 °C

until further use. An aliquot of each urine sample (7 mL) was concentrated to a final volume of 0.5 uL by centrifugal ultrafiltration using a VivaSpin 15R (10 KDa MWCO, Sartorius) at 5000 x *g* for 20 min. The concentrated urine samples were then quantified by a Bradford quantification assay, using Bovine Serum Albumin (BSA) to perform a calibration curve.

### Protein Digestion

Urinary proteome digestion was performed by a modified Filtered Aided Sample Preparation (FASP) method [20,21], as described by Carvalho *et al.* [22,23]. The total protein digested ranged from 25 to 50 µg being diluted in Milli-Q water and a solution of 1 M urea, 50 mM NaCl, 0.001% SDS, and 50 mM TRIS-HCl pH 8.0 performing a total volume of 400 µL. The concentration of the resulting peptides was then quantified by a tryptophan emission assay [24].

### LC-MS/MS Analysis

LC-MS/MS analysis was performed using UltiMate 3000 ultra-high performance liquid chromatographer from Thermo Scientific, coupled to Ultra High-Resolution Quadrupole Time-of-Flight (UHR-QTOF) IMPACT HD mass spectrometer from Bruker Daltonics equipped with a CaptiveSpray nanoBosster™ using acetonitrile as a dopant. 3 µL of the sample with a total peptide concentration of 0.1 µg/µL were loaded onto a µPAC™ Trapping column and desalted for 2.7 min with 3% (v/v) acetonitrile (ACN) in 0.1% (v/v) aqueous formic acid (FAaq) at a flow rate of 15 µL/min. Then the peptides were separated using an analytical column (200 cm µPACTM PharmaFluidics) with a linear gradient at 500 nL/min (mobile phase A: FAaq 0.1% (v/v); mobile phase B: 99.9% (v/v) ACN and 0.1% (v/v) FAaq) 0-2 min from 3% to 5% of mobile phase B, 2-90 min from 5% to 35% of mobile phase B, 90-100 min 35% to 85% B, 100-120 min at 85% B. Chromatographic separation was carried out at 35°C. MS acquisition was set to MS (2 Hz) cycles, followed by MS/MS (8-32 Hz), cycle time 3.0 seconds, active exclusion, exclude after one spectrum, release after 2 min. The precursor was reconsidered if its current intensity was 3.0 higher than the previous intensity and intensity threshold for fragmentation of 2500 counts.

### Bioinformatics Analysis Data Analysis and Processing


Relative label-free quantification was carried out using MaxQuant software V1.6.0.16 [25]. All raw files were processed in a single run using default settings. Database searches were performed using the Andromeda search engine with the UniProt-SwissProt Human database as a reference and a database of common contaminants [26]. Protein intensities obtained from the LC-MS/MS data processed within MaxQuant software were used to perform the Total Protein Approach (TPA) [18]. TPA allows for estimating absolute protein quantities from a label-free

proteomics approach. Protein intensities were then used and transformed into TPA values using the equation presented in **Figure 1**. Subsequently, protein absolute values were converted to pmol of protein per mg of total protein. Furthermore, data processing was performed using Perseus V2.0.11, with default settings [27]. Briefly, protein TPA values were log<sub>2</sub>-transformed and statistically evaluated using a volcano plot based on a two-sample Student's t-test, with a false discovery rate (FDR) threshold of 0.05 and an S0 parameter of 0.1.

**Results and Discussion**

As illustrated in **Figure 1**, midstream second-morning urine

samples were collected from 24 patients with histologically confirmed diagnoses, 12 with non-muscle-invasive bladder cancer, NMIBC and 12 with muscle-invasive bladder cancer MIBC. The samples were processed and analysed using a standardized protocol comprising protein concentration, reduction, alkylation, and enzymatic digestion via a modified Filter-Aided Sample Preparation, FASP, method, followed by high-resolution LC-MS/MS analysis. Protein quantification was carried out using the Total Protein Approach, TPA, which allows for absolute, label-free measurement of protein abundances across all samples. This strategy enabled precise comparative analysis between the two clinical groups and facilitated the identification of protein expression patterns associated with tumor invasiveness.




**Figure 1 |** Workflow for urinary proteome analysis. A total of 24 urine samples were collected, including 12 from patients with non-muscle-invasive bladder cancer (NMIBC) and 12 from those with muscle-invasive bladder cancer (MIBC). Samples underwent standardised pre-processing, followed by protein reduction, alkylation, and enzymatic digestion using the Filter-Aided Sample Preparation, FASP, method. The resulting peptides were analysed by nano-HPLC coupled to ESI-MS/MS. Protein quantification and biomarker discovery were conducted using the Total Protein Approach, TPA.



**Figure 2a** presents a volcano plot comparing the urinary proteomes of patients with MIBC and NMIBC. The analysis revealed 153 and 318 proteins with higher abundance in the NMIBC and MIBC groups, respectively. This distinct

proteomic separation underscores the potential of urinary protein profiling as a non-invasive strategy for accurately identifying high-risk, muscle-invasive bladder cancer at the time of diagnosis.



**Figure 2 | Urinary TPA levels (pmol protein/mg proteome) for potential biomarkers in patients diagnosed with NMIBC and MIBC urine samples.** **a.** Volcano plot showing proteome changes in urine of NMIBC patients (n=12) and MIBC (n=12). The red and blue dots represent proteins showing statistically significant proteins upregulated and downregulated, respectively. The grey dots represent proteins that are not statistically significant according to a Student's t-test (FDR 0.05 and SO 0.1). **b, c, d, e** and **f.** Variation in the TPA level of the POSTN, IGLV3-21, IGHV3-49, IGHV5-51, and C4BPB proteins in urine samples of patients diagnosed with NMIBC and MIBC. Sens = Sensibility and Spec = Specificity. Red dots: TPA concentrations for MIBC patients ( $\bar{x} \pm SD$  pmol protein/mg total proteome; n=2 technical replicates). Blue line: Average TPA concentrations for NMIBC group for POSTN, IGLV3-21, IGHV3-49, IGHV5-51 and C4BPB proteins ( $\bar{x} \pm SD$ , pmol protein/mg proteome). Concentrations were, respectively,  $0.03 \pm 0.02$  (n= 8, max: 0.07; min: 0.003 );  $18 \pm 10$  (n= 12, max: 46.5; min: 6.5);  $2 \pm 1$  (n= 10, max: 4.4 ; min: 0.68);  $16 \pm 5$  (n= 12, max: 30 ; min: 8);  $0.4 \pm 0.4$  (n= 9, max: 1.4; min: 0.05).

The complete list of proteins is presented in Table 1, in epithelial ovarian carcinoma patients, and it is also supplementary material, **T1SM**. The identification of proteins associated with platinum resistance [28]. In this line, Xu *et al.* significantly elevated in the urine of patients with MIBC, have found that POSTN promotes the proliferation and compared to those with non-invasive disease, reveals metastasis of osteosarcoma by increasing cell survival and by promising biomarkers linked to tumour aggressiveness and activating the PI3K/Akt pathway [29]. On the other hand, Inoue *et al.* have found that POSTN suppresses in vivo invasiveness via PDK1/Akt/mTOR signalling pathway in a mouse orthotopic transition (EMT), which are key processes in cancer invasion and metastasis. The information available in the literature significantly higher in MIBC urine samples (**Figure 2b**), about the roles of this protein is contradictory. On the one hand, Sung *et al.* have found that high POSTN expression in disease. the cancer microenvironment is correlated with poor prognosis

Increased urinary levels of immunoglobulin variable regions, specifically IGLV3-21 (**Figure 2c**), IGHV3-49 (**Figure 2d**), and IGHV5-51 (**Figure 2e**) were observed in MIBC patients. These findings may reflect tumour-infiltrating B-cell activation or ectopic immunoglobulin production by tumour cells, a process increasingly recognised in several solid tumors [31]. Evidence suggests that cancer cells can also produce Immunoglobulins (Igs), called cancer-derived Igs. Although this form of Igs has the same basic structure as the Igs from B cells, it has some significant differences, such as limited sequence variation and unusual glycosylation patterns. Unlike B cell-derived Igs, which work to protect the body as part of the immune system, cancer-derived Igs help tumours grow. It supports cancer cells by making them more aggressive, helping them escape the immune system, causing inflammation, and encouraging platelets in the blood to stick together, which may help the tumour survive [31]. Our data aligns with these findings, and we have found that IGLV3-21, IGHV3-49, and IGHV5-51 can also be used as biomarkers to differentiate invasive from non-invasive muscle bladder cancer patients.

Additionally, the detection of C4b-binding protein beta chain (C4BPB, Fig. 2e) adds further value to this biomarker panel. C4BP is a key regulator of the complement system and has a complex structure comprising one  $\beta$ -chain and seven  $\alpha$ -chains. These chains are mainly formed by three (in the  $\beta$ -chain) and eight (in the  $\alpha$ -chains) complement control protein (CCP) modules, followed by a unique carboxy-terminal region that allows the chains to polymerise. C4BP plays a vital role in immune regulation by interacting with several molecules, including C4b, protein S, Arp, and heparin [32,33].

Upregulation of complement inhibitors like C4BPB by tumour cells is thought to promote immune evasion and protect against complement-mediated cytotoxicity. Its overexpression in urine from invasive cases suggests active immune regulatory mechanisms contributing to tumour survival and stromal invasion.

Taken together, the increased urinary abundance of POSTN, IGHV segments, and C4BPB in invasive bladder cancer points to a multi-pathway signature encompassing ECM remodelling, immune modulation, and B-cell activity. This molecular profile holds strong potential for development into a non-invasive biomarker panel for identifying high-risk bladder cancer cases and guiding prognosis or treatment stratification [34].

## Conclusion

This study demonstrates that the Total Protein Approach can effectively uncover distinct urinary proteomic patterns that differentiate NMIBC from MIBC. We identified 471 proteins with differential abundance through absolute, label-free quantification, several of which emerged as promising

candidates for non-invasive biomarkers indicative of tumour invasiveness. Our findings support urine proteomics, specifically the TPA, as a scalable and therapeutically relevant method for identifying the molecular hallmarks of bladder cancer invasiveness. This study adds to the developing field of liquid biopsies by providing a promising, non-invasive technique for early risk classification, long-term disease monitoring, and potentially guiding therapy decisions. Future validation in larger, independent cohorts will be required to transfer this proteomic signature into routine clinical application.

## Acknowledgements

PROTEOMASS Scientific Society is acknowledged by the funding provided to the Laboratory for Biological Mass Spectrometry Isabel Moura (#PM001/2024, #PM001/2019 and #PM003/2016). This work received support from Fundação para a Ciência e a Tecnologia and Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES) through the projects LA/P/0008/2020 DOI 10.54499/LA/P/0008/2020, UIDP/50006/2020 DOI 10.54499/UIDP/50006/2020 and UIDB/50006/2020 DOI 10.54499/UIDB/50006/2020. HMS acknowledges the Associate Laboratory for Green Chemistry – LAQV (LA/P/0008/2020) DOI 10.54499/LA/P/0008/2020 funded by FCT/MCTES for his research contract. AQF thanks FCT/MCTES for his PhD grant reference 2023.00528.BD. IFD thanks FCT/MCTES for his PhD grant reference 2024.00745.BD.

## Authors' contributions

J.L.C., C.L., L.C.P., M.M. and H.M.S. designed the experimental work. J.L.C., C.L. and H.M.S. and provided financial support. J.M.R.A.M., L.B.C., A.Q.F. and I.F.D. performed the laboratory work and data analysis under the supervision of L.B.C., H.M.S. and J.L.C. J.L.C. drafted the manuscript. J.M.R.A.M., L.B.C., I.F.D., A.Q.F., J.L.C., C.L., L.C.P., M.M., and H.M.S. revised the drafted version, corrected it, and made valuable suggestions. L.C.P. and M.M. managed patient interventions and provided samples and medical data.

## Funding

PROTEOMASS Scientific Society, #PM001/2019, #PM003/2016. Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES), LA/P/0008/2020 DOI 10.54499/LA/P/0008/2020, UIDP/50006/2020 DOI 10.54499/UIDP/50006/2020 and UIDB/50006/2020 DOI 10.54499/UIDB/50006/2020.

## References

[1] Zhang, Y. et al. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. *J Glob Health* 13, 04109 (2023).

- [2] Saginala, K. et al. Epidemiology of bladder cancer. *Medical Sciences* 8, 15 (2020).
- [3] Tanaka, M. F. & Sonpavde, G. Diagnosis and management of urothelial carcinoma of the bladder. *Postgrad Med* 123, 43–55 (2011).
- [4] Narter, K. F. & Sabuncu, K. Invasion mechanisms of bladder cancer: A molecular review. *Journal of Urological Surgery* 3, 66–73 (2016).
- [5] Li, R. et al. Bladder-sparing therapy for bacillus calmette-guérin-unresponsive non-muscle-invasive bladder cancer: international bladder cancer group recommendations for optimal sequencing and patient selection. *Eur Urol* 86, 516–527 (2024).
- [6] Park, J. C., Citrin, D. E., Agarwal, P. K. & Apolo, A. B. Multimodal management of muscle-invasive bladder cancer. *Curr Probl Cancer* 38, 80–108 (2014).
- [7] Chen, S. et al. Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced raman spectroscopy. *Biomed Opt Express* 10, 3533 (2019).
- [8] Bedke, J. et al. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition. *Urologic Oncology: Seminars and Original Investigations* 41, 461–475 (2023).
- [9] Zoqlam, R. et al. Emerging molecular mechanisms and genetic targets for developing novel therapeutic strategies for treating bladder diseases. *European Journal of Pharmaceutical Sciences* 173, 106167 (2022).
- [10] Babjuk, M. Transurethral resection of non-muscle-invasive bladder cancer. *European Urology Supplements* 8, 542–548 (2009).
- [11] Medeiros, M., Capelo-Martínez, J. L., Baptista Carreira dos Santos, H. M., Botelho de Carvalho, L. A. & Campos Pinheiro, L. The High Resolution MASS spectrometry in Personalised Medicine: Retinol-Binding Protein 4 as a Candidate Biomarker Predictor of Progression in Bladder Urothelial Carcinoma. *Acta Urológica Portuguesa* 38, 12–17 (2024).
- [12] Hurst, C. D. et al. Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. *Cancer Cell* 32, 701–715.e7 (2017).
- [13] Schwarzova, L., Varchulova Novakova, Z., Danisovic, L. & Ziaran, S. Molecular classification of urothelial bladder carcinoma. *Mol Biol Rep* 50, 7867–7877 (2023).
- [14] Sequeira-Antunes, B. & Ferreira, H. A. Urinary biomarkers and point-of-care urinalysis devices for early diagnosis and management of disease: A review. *Biomedicines* 11, 1051 (2023).
- [15] Carvalho, S. et al. Phenotypic analysis of urothelial exfoliated cells in bladder cancer via microfluidic immunoassays: Sialyl-Tn as a novel biomarker in liquid biopsies. *Front Oncol* 10, (2020).
- [16] Wiśniewski, J. R., Koepsell, H., Gizak, A. & Rakus, D. Absolute protein quantification allows differentiation of cell-specific metabolic routes and functions. *Proteomics* 15, 1316–1325 (2015).
- [17] Wiśniewski, J. R. & Mann, M. A proteomics approach to the protein normalization problem: selection of unvarying proteins for MS-Based proteomics and western blotting. *J Proteome Res* 15, 2321–2326 (2016).
- [18] Wiśniewski, J. R. Label-Free and Standard-Free Absolute Quantitative Proteomics Using the “Total Protein” and “Proteomic Ruler” Approaches. in 49–60 (2017). doi:10.1016/bs.mie.2016.10.002.
- [19] Carvalho, L. B., Capelo-Martínez, J. L., Lodeiro, C., Wiśniewski, J. R. & Santos, H. M. Snap-heated freeze-free preservation and processing of the urine proteome using the combination of stabilizer-based technology and filter aided sample preparation. *Anal Chim Acta* 1076, 82–90 (2019).
- [20] Wiśniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. *Nat Methods* 6, 359–362 (2009).
- [21] Wiśniewski, J. R. Filter Aided Sample Preparation – A tutorial. *Anal Chim Acta* 1090, 23–30 (2019).
- [22] Carvalho, L. B. et al. Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics. *Communications Medicine* 3, 8 (2023).
- [23] Carvalho, L. B. et al. Biochemical network analysis of protein-protein interactions to follow-up T1 bladder cancer patients. *J Proteomics* 278, 104865 (2023).
- [24] Wiśniewski, J. R. & Gaugaz, F. Z. Fast and sensitive total protein and peptide assays for proteomic analysis. *Anal Chem* 87, 4110–4116 (2015).
- [25] Tyanova, S. et al. Visualization of LC-MS/MS proteomics data in MaxQuant. *Proteomics* 15, 1453–1456 (2015).
- [26] Cox, J. et al. Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment. *J Proteome Res* 10, 1794–1805 (2011).

- [27] Tyanova, S. & Cox, J. Perseus: a bioinformatics platform for integrative analysis of proteomics data in cancer research. in 133–148 (2018). doi:10.1007/978-1-4939-7493-1\_7.
- [28] Sung, P.-L. et al. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma. *Oncotarget* 7, 4036–4047 (2016).
- [29] Xu, C. et al. Periostin promotes the proliferation and metastasis of osteosarcoma by increasing cell survival and activates the PI3K/Akt pathway. *Cancer Cell Int* 22, 34 (2022).
- [30] Kim, C. J. et al. Periostin suppresses in vivo invasiveness via PDK1/Akt/mTOR signaling pathway in a mouse orthotopic model of bladder cancer. *Oncol Lett* 13, 4276–4284 (2017).
- [31] Cui, M. et al. Immunoglobulin expression in cancer cells and Its critical roles in tumorigenesis. *Front Immunol* 12, (2021).
- [32] Villoutreix, B. O., Blom, A. M., Webb, J. & Dahlbäck, B. The complement regulator C4b-binding protein analyzed by molecular modeling, bioinformatics and computer-aided experimental design. *Immunopharmacology* 42, 121–134 (1999).
- [33] Werner, L. M. & Criss, A. K. Diverse functions of C4b-binding protein in health and disease. *The Journal of Immunology* 211, 1443–1449 (2023).
- [34] Blom, A. M., Villoutreix, B. O. & Dahlbäck, B. Complement inhibitor C4b-binding protein—friend or foe in the innate immune system? *Mol Immunol* 40, 1333–1346 (2004).